<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ISOPTO CARPINE- pilocarpine hydrochlorideÂ solutionÂ </strong><br>Alcon Laboratories, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">
<span class="Bold">These highlights do not include all the information needed to use IsoptoÂ® Carpine safely and effectively. See full prescribing information for IsoptoÂ® Carpine.</span><br><br><span class="Bold">IsoptoÂ® Carpine (pilocarpine hydrochloride ophthalmic solution) 1%, 2% and 4%</span><br><span class="Bold">Initial U.S. Approval: 1974</span>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">IsoptoÂ® Carpine is a muscarinic cholinergic agonist indicated for </p>
<ul class="Disc">
<li>The reduction of elevated intraocular pressure (IOP) in patients with open-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> or <span class="product-label-link" type="condition" conceptid="381290" conceptname="Ocular hypertension">ocular hypertension</span> (<span class="Underline"><a href="#splSection1">1.1</a></span>)</li>
<li>The management of acute angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> (<span class="Underline"><a href="#splSection2">1.2</a></span>)</li>
<li>The prevention of postoperative elevated IOP associated with laser surgery (<span class="Underline"><a href="#splSection3">1.3</a></span>)</li>
<li>The induction of <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span> (<span class="Underline"><a href="#splSection4">1.4</a></span>)</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc"><li>Instill one drop in the eye(s) up to four times daily (<span class="Underline"><a href="#splSectionPLRDosageAdministration">2</a></span>).</li></ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disc"><li>Solution containing 1% (10 mg/mL), 2% (20 mg/mL) or 4% (40 mg/mL) pilocarpine hydrochloride (<span class="Underline"><a href="#splSectionPLRDosageFormsStrength">3</a></span>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">None.  (<a href="#section-4">4</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Poor illumination: Exercise caution in night driving and other hazardous occupations in poor illumination (<span class="Underline"><a href="#splSection11">5.1</a></span>).</li>
<li>Pre-existing retinal disease: Rare cases of <span class="product-label-link" type="condition" conceptid="378414" conceptname="Retinal detachment">retinal detachment</span> have been reported; a thorough examination of the retina including funduscopy is advised in all patients prior to the initiation of therapy (<span class="Underline"><a href="#splSection12">5.2</a></span>).</li>
<li><span class="product-label-link" type="condition" conceptid="4274964" conceptname="Iritis">Iritis</span>: Caution is advised in patients with <span class="product-label-link" type="condition" conceptid="4274964" conceptname="Iritis">iritis</span>. (<span class="Underline"><a href="#splSection13">5.3</a></span>)</li>
<li><span class="product-label-link" type="condition" conceptid="374139" conceptname="Buphthalmos">Congenital glaucoma</span>: Caution is advised in pediatric patients with primary <span class="product-label-link" type="condition" conceptid="374139" conceptname="Buphthalmos">congenital glaucoma</span> for control of IOP as cases of a paradoxical increase in IOP have been reported. (<span class="Underline"><a href="#splSection14">5.4</a></span>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions are <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>/browache, accommodative change, <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">eye irritation</span>, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, and/or <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">visual impairment</span> (<span class="Underline"><a href="#splSectionPLRAdverseReactions">6.1</a></span>). </p>
<p class="Highlighta">Â Â Â Â Â Â Â  </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Alcon Laboratories, Inc. at 1-800-757-9195 or FDA at 1-800-FDA-1088 or </span><span class="Bold Underline">www.fda.gov/medwatch</span>. </p>
</div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 8/2012</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">
1	INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">
2	DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">
2.1	Reduction of Elevated Intraocular Pressure (IOP) in Patients with Open-Angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span> or <span class="product-label-link" type="condition" conceptid="381290" conceptname="Ocular hypertension">Ocular Hypertension</span></a></h2>
<h2><a href="#section-2.2" class="toc">
2.2	Management of Acute Angle-Closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span></a></h2>
<h2><a href="#section-2.3" class="toc">
2.3	Prevention of Postoperative Elevated IOP Associated with Laser Surgery</a></h2>
<h2><a href="#section-2.4" class="toc">
2.4	Induction of <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">Miosis</span></a></h2>
<h2><a href="#section-2.5" class="toc">
2.5	Use with Other Topical Ophthalmic Medications</a></h2>
<h2><a href="#section-2.6" class="toc">
2.6	Use in Pediatric Patients</a></h2>
<h1><a href="#section-3" class="toc">
3	DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">
4	CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">
5	WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">
5.1	Poor Illumination</a></h2>
<h2><a href="#section-5.2" class="toc">
5.2	Pre-existing Retinal Disease</a></h2>
<h2><a href="#section-5.3" class="toc">
5.3	<span class="product-label-link" type="condition" conceptid="4274964" conceptname="Iritis">Iritis</span></a></h2>
<h2><a href="#section-5.4" class="toc">
5.4	Primary <span class="product-label-link" type="condition" conceptid="374139" conceptname="Buphthalmos">Congenital Glaucoma</span></a></h2>
<h2><a href="#section-5.5" class="toc">
5.5	Contact Lens Wear</a></h2>
<h1><a href="#section-6" class="toc">
6	ADVERSE REACTIONS</a></h1>
<h1><a href="#section-7" class="toc">
8	USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-7.1" class="toc">
8.1	Pregnancy</a></h2>
<h2><a href="#section-7.2" class="toc">
8.3	Nursing Mothers</a></h2>
<h2><a href="#section-7.3" class="toc">
8.4	Pediatric Use</a></h2>
<h2><a href="#section-7.4" class="toc">
8.5	Geriatric Use</a></h2>
<h1><a href="#section-8" class="toc">
10	OVERDOSAGE</a></h1>
<h1><a href="#section-9" class="toc">
11	DESCRIPTION</a></h1>
<h1><a href="#section-10" class="toc">
12	CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-10.1" class="toc">
12.1	Mechanism of Action</a></h2>
<h2><a href="#section-10.2" class="toc">
12.3	Pharmacokinetics</a></h2>
<h1><a href="#section-11" class="toc">
13	NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">
13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-12" class="toc">
14	CLINICAL STUDIES</a></h1>
<h1><a href="#section-13" class="toc">
16	HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-14" class="toc">
17	PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-14.1" class="toc">
17.1	Avoiding Contamination of the Product</a></h2>
<h2><a href="#section-14.2" class="toc">
17.2	Night Driving</a></h2>
<h2><a href="#section-14.3" class="toc">
17.3	Accommodative Spasm</a></h2>
<h2><a href="#section-14.4" class="toc">
17.4	Contact Lens Wear</a></h2>
<h2><a href="#section-14.5" class="toc">
17.5	Concomitant Topical Ocular Therapy</a></h2>
<h2><a href="#section-14.6" class="toc">
17.6	Systemic Exposure</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="SPLSERV-D86BD9D8-9C02-8F93-0ACE-2699F419C147"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="splSectionPLRIndicationsUsage"></a><a name="section-1"></a><p></p>
<h1>
1	INDICATIONS AND USAGE</h1>
<p class="First"><span class="Bold">IsoptoÂ® Carpine is indicated for the:</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection22"></a><a name="section-1.1"></a><p></p>
<h2>
1.1	Reduction of Elevated Intraocular Pressuare (IOP) in Patients with Open-Angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span> or <span class="product-label-link" type="condition" conceptid="381290" conceptname="Ocular hypertension">Ocular Hypertension</span></h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection23"></a><a name="section-1.2"></a><p></p>
<h2>1.2	Management of Acute Angle-Closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span></h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection24"></a><a name="section-1.3"></a><p></p>
<h2>
1.3	Prevention of Postoperative Elevated IOP Associated with Laser Surgery</h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection25"></a><a name="section-1.4"></a><p></p>
<h2>
1.4	Induction of <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">Miosis</span></h2>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="splSectionPLRDosageAdministration"></a><a name="section-2"></a><p></p>
<h1>
2	DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection5"></a><a name="section-2.1"></a><p></p>
<h2>
2.1	Reduction of Elevated Intraocular Pressure (IOP) in Patients with Open-Angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span> or <span class="product-label-link" type="condition" conceptid="381290" conceptname="Ocular hypertension">Ocular Hypertension</span></h2>
<p class="First">One drop of IsoptoÂ® Carpine 1%, 2% or 4% should be applied topically in the eye(s) up to four times daily. Pilocarpine-naÃ¯ve patients should be started on the 1% concentration as higher concentrations are often not tolerated initially. The frequency of instillation and concentration of IsoptoÂ® Carpine are determined by the severity of the elevated intraocular pressure and miotic response of the patient.<br><br>To limit systemic exposure to pilocarpine, patients may be instructed to perform punctal occlusion for 2 minutes after instillation of IsoptoÂ® Carpine ophthalmic solution.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection6"></a><a name="section-2.2"></a><p></p>
<h2>
2.2	Management of Acute Angle-Closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span></h2>
<p class="First">Prior to IsoptoÂ® Carpine use, treatment with secretory suppressants and hyperosmotic agents may be needed to lower IOP below 50 mmHg and relieve iris <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>. For initial management of acute angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, one drop of IsoptoÂ® Carpine 1% or 2% may be applied topically in the eye(s) up to three times over a 30-minute period.<br><br>If laser iridoplasty or iridomy is used to break the attack, one drop of IsoptoÂ® Carpine 4% should be administered prior to the procedure. Following laser iridoplasty, one drop of IsoptoÂ® Carpine 1% should be administered four times daily until an iridotomy can be performed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection7"></a><a name="section-2.3"></a><p></p>
<h2>
2.3	Prevention of Postoperative Elevated IOP Associated with Laser Surgery</h2>
<p class="First">One drop of IsoptoÂ® Carpine 1%, 2% or 4% (or two drops administered five minutes apart) should be applied topically in the eye(s) 15 to 60 minutes prior to surgery.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection8"></a><a name="section-2.4"></a><p></p>
<h2>
2.4	Induction of <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">Miosis</span></h2>
<p class="First">One drop of IsoptoÂ® Carpine 1%, 2% or 4% (or two drops administered five minutes apart) should be applied topically in the eye(s).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection9"></a><a name="section-2.5"></a><p></p>
<h2>
2.5	Use with Other Topical Ophthalmic Medications</h2>
<p class="First">IsoptoÂ® Carpine may be used in combination with beta-blockers, carbonic anhydrase inhibitors, sympathomimetics or hyperosmotic agents. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection10"></a><a name="section-2.6"></a><p></p>
<h2>
2.6	Use in Pediatric Patients</h2>
<p class="First">In children under 2 years of age, one drop of IsoptoÂ® Carpine 1% should be applied topically in the eye(s) three times daily. Children 2 years of age and over should be dosed as for adults. For the induction of <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span> prior to goniotomy or trabeculotomy in children, one drop of IsoptoÂ® Carpine 1% or 2% should be applied topically in the eye 15 to 60 minutes prior to surgery.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="splSectionPLRDosageFormsStrength"></a><a name="section-3"></a><p></p>
<h1>
3	DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Bottle filled with 15 mL of 1% (10 mg/mL), 2% (20 mg/mL) or 4% (40 mg/mL) pilocarpine hydrochloride sterile ophthalmic solution.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="splSectionPLRContraindications"></a><a name="section-4"></a><p></p>
<h1>
4	CONTRAINDICATIONS</h1>
<p class="First">None.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="splSectionPLRWarnings"></a><a name="section-5"></a><p></p>
<h1>
5	WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection11"></a><a name="section-5.1"></a><p></p>
<h2>
5.1	Poor Illumination</h2>
<p class="First">Patients should be advised to exercise caution in night driving and other hazardous occupations in poor illumination. In addition, miotics may cause accommodative spasm. Patients should be advised not to drive or use machinery if vision is not clear.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection12"></a><a name="section-5.2"></a><p></p>
<h2>
5.2	Pre-existing Retinal Disease</h2>
<p class="First">As with all miotics, rare cases of <span class="product-label-link" type="condition" conceptid="378414" conceptname="Retinal detachment">retinal detachment</span> have been reported when used in certain susceptible individuals and those with pre-existing retinal disease; therefore, a thorough examination of the retina including funduscopy is advised in all patients prior to the initiation of therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection13"></a><a name="section-5.3"></a><p></p>
<h2>
5.3	<span class="product-label-link" type="condition" conceptid="4274964" conceptname="Iritis">Iritis</span></h2>
<p class="First">IsoptoÂ® Carpine is not recommended to be used when <span class="product-label-link" type="condition" conceptid="4274964" conceptname="Iritis">iritis</span> is present.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection14"></a><a name="section-5.4"></a><p></p>
<h2>
5.4	Primary <span class="product-label-link" type="condition" conceptid="374139" conceptname="Buphthalmos">Congenital Glaucoma</span></h2>
<p class="First">Caution is advised when using IsoptoÂ® Carpine in pediatric patients with primary <span class="product-label-link" type="condition" conceptid="374139" conceptname="Buphthalmos">congenital glaucoma</span> for control of intraocular pressure (IOP) as cases of a paradoxical increase in IOP have been reported. In addition, the use of IsoptoÂ® Carpine is not recommended in pediatric patients diagnosed with <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma secondary</span> to anterior segment dysgenesis or <span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">uveitis</span> (especially if <span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">uveitis</span> is active).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection15"></a><a name="section-5.5"></a><p></p>
<h2>
5.5	Contact Lens Wear</h2>
<p class="First">Contact lens wearers should be advised to remove their lenses prior to the instillation of IsoptoÂ® Carpine ophthalmic solution and to wait 10 minutes after dosing before reinserting their contact lenses.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="splSectionPLRAdverseReactions"></a><a name="section-6"></a><p></p>
<h1>
6	ADVERSE REACTIONS</h1>
<p class="First"><span class="Bold">Clinical Studies Experience<br></span><br>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.<br><br>The safety data described below reflect exposure in four controlled clinical trials of 90 days to 2 years duration in 317 patients diagnosed with open-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> or <span class="product-label-link" type="condition" conceptid="381290" conceptname="Ocular hypertension">ocular hypertension</span>. In the four clinical trials, patients were treated with IsoptoÂ® Carpine 2%, two to four times daily or with pilocarpine 1%, 1.75% or 2% in fixed combination with betaxolol 0.25%, two or three times daily.The most frequently reported adverse reactions occurring in â‰¥ 5% of patients in the pilocarpine 2% populations were: <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>/browache, accommodative change, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">eye irritation</span>, <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">visual impairment</span> (dim, dark, or â€œjumpingâ€? vision), and <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>.<br><br>The adverse reaction profile reported for the use of IsoptoÂ® Carpine in pediatric patients is comparable to that seen in adult patients.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="splSectionPLRPopulations"></a><a name="section-7"></a><p></p>
<h1>
8	USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="splSectionPLRPregnancy"></a><a name="section-7.1"></a><p></p>
<h2>
8.1	Pregnancy</h2>
<p class="First">Pregnancy. Category C. Animal reproduction studies have not been conducted with pilocarpine hydrochloride. It is also not known whether pilocarpine hydrochloride can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. IsoptoÂ® Carpine should be given to a pregnant woman only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="splSectionPLRNursing"></a><a name="section-7.2"></a><p></p>
<h2>
8.3	Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when IsoptoÂ® Carpine is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="splSectionPLRPediatric"></a><a name="section-7.3"></a><p></p>
<h2>
8.4	Pediatric Use</h2>
<p class="First">Safety and effectiveness of pilocarpine hydrochloride ophthalmic solution in pediatric patients have been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="splSectionPLRGeriatric"></a><a name="section-7.4"></a><p></p>
<h2>
8.5	Geriatric Use</h2>
<p class="First">No overall differences in safety or effectiveness have been observed between elderly and younger patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="splSectionPLROverdose"></a><a name="section-8"></a><p></p>
<h1>
10	OVERDOSAGE</h1>
<p class="First">Systemic toxicity following topical ocular administration of pilocarpine is rare, but occasionally patients who are sensitive may develop <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> and gastrointestinal <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">overactivity</span> following the suggested dosage and administration. Overdosage can produce <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">salivation</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span> and slowing of the pulse and a decrease in blood pressure. In moderate overdosage, spontaneous recovery is to be expected and is aided by intravenous fluids to compensate for <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>. For patients demonstrating severe <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>, atropine, the pharmacologic antagonist to pilocarpine, should be used.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="splSectionPLRDescription"></a><a name="section-9"></a><p></p>
<h1>
11	DESCRIPTION</h1>
<p class="First">IsoptoÂ® Carpine (pilocarpine hydrochloride ophthalmic solution) is a cholinergic agonist prepared as a sterile topical ophthalmic solution. The active ingredient is represented by the chemical structure:</p>
<div class="Figure"><img alt="Chemical Diagram" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=22e4c7f4-bbd0-4e74-85da-bb56fc377568&amp;name=chemical.jpg"></div>
<p>Established name: pilocarpine hydrochloride<br><br>Chemical name: 2(3<span class="Italics">H</span>)-furanone, 3-ethyldihydro-4-[(1-methyl-1<span class="Italics">H</span>-imidazol-5-yl)-methyl]- monohydrochloride, (3S-<span class="Italics">cis</span>)-. Molecular Formula: C<span class="Sub">11</span>H<span class="Sub">16</span>N<span class="Sub">2</span>O<span class="Sub">2</span> â€¢ HCl Molecular Weight: 244.72.<br><br>Each mL of IsoptoÂ® Carpine (pilocarpine hydrochloride ophthalmic solution) contains: <span class="Bold">Active: </span>pilocarpine hydrochloride 1% (10 mg/mL), 2% (20 mg/mL), or 4% (40 mg/mL).Â <br><br><span class="Bold">Preservative: </span>benzalkonium chloride 0.01%.Â <br><br><span class="Bold">Inactives: </span>hypromellose 2910, boric acid, sodium citrate, sodium chloride (present in 1% only); hydrochloric acid and/or sodium hydroxide (to adjust pH); purified water. IsoptoÂ® Carpine has a pH of 3.5 to 5.5 and an <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> of 290 to 350 mOsm/kg (1% and 2% products) and 550 to 600 mOsm/kg (4% product).</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="splSectionPLRClinicalPharm"></a><a name="section-10"></a><p></p>
<h1>
12	CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="splSectionPLRMechAction"></a><a name="section-10.1"></a><p></p>
<h2>
12.1	Mechanism of Action</h2>
<p class="First">Pilocarpine hydrochloride is a direct acting cholinergic parasympathomimetic agent which acts through direct stimulation of muscarinic receptors and smooth muscle such as the iris and secretory glands.Â Pilocarpine contracts the ciliary muscle, causing increased <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span> on the scleral spur and opening of the trabecular meshwork spaces to facilitate outflow of aqueous humor. Outflow resistance is reduced, lowering intraocular pressure (IOP). Pilocarpine also produces <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span> through contraction of the iris sphincter muscle. <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">Miosis</span> relieves appositional angle narrowing and closure, which lowers IOP in certain types of angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="splSectionPLRPharmacokinetics"></a><a name="section-10.2"></a><p></p>
<h2>
12.3	Pharmacokinetics</h2>
<p class="First">Systemic exposure to pilocarpine was evaluated in 14 healthy subjects administered 2 drops of IsoptoÂ® Carpine (pilocarpine hydrochloride ophthalmic solution) 4% to both eyes four times daily for eight days. A comparison of C<span class="Sub">max</span> values on Days 5 and 8 indicated that pilocarpine concentrations in plasma reached steady-state following topical administration of IsoptoÂ® Carpine 4%. The mean (SD) C<span class="Sub">max</span> and AUC<span class="Sub">0-last</span> values on Day 8 were 3.7 (3.2) ng/mL and 7.7 (8.4) ngÃ—hour/mL, respectively. The T<span class="Sub">max</span> values on Day 8 ranged from 0.5 to 1 hour.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="splSectionPLRNonClinical"></a><a name="section-11"></a><p></p>
<h1>
13	NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="splSectionPLRPrecautionsCarcinogen"></a><a name="section-11.1"></a><p></p>
<h2>
13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">There have been no long-term studies done using pilocarpine hydrochloride in animals to evaluate carcinogenic potential.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="splSectionPLRClinicalStudies"></a><a name="section-12"></a><p></p>
<h1>
14	CLINICAL STUDIES</h1>
<p class="First">In clinical trials reported in the medical literature, pilocarpine ophthalmic solution reduced intraocular pressure (IOP) by 3-7 mmHg in patients with open-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>. Pilocarpine ophthalmic solution has also been shown to be effective in the induction of <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span>, in the prevention of postoperative elevated IOP, and in the management of acute angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="splSectionPLRHowSupplied"></a><a name="section-13"></a><p></p>
<h1>
16	HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">IsoptoÂ® Carpine (pilocarpine hydrochloride ophthalmic solution) 1%, 2% and 4% is supplied sterile in natural low density polyethylene plastic ophthalmic DROP-TAINERÂ® dispensers and green low density polyethylene tips with green polypropylene caps.<br>15 mL in 15 mL bottles<br>1%: <span class="Bold">NDC </span>0998-0203-15<br>2%: <span class="Bold">NDC </span>0998-0204-15<br>4%: <span class="Bold">NDC </span>0998-0206-15<br><br><span class="Bold">STORAGE: </span>Store at 15Â°- 25Â°C (59Â° - 77Â°F) and protect from freezing.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="splSectionPLRPatientInfo"></a><a name="section-14"></a><p></p>
<h1>
17	PATIENT COUNSELING INFORMATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection16"></a><a name="section-14.1"></a><p></p>
<h2>
17.1	Avoiding Contamination of the Product</h2>
<p class="First">Do not touch dropper tip to any surface, as this may contaminate the contents.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection17"></a><a name="section-14.2"></a><p></p>
<h2>
17.2	Night Driving</h2>
<p class="First">Caution is advised with night driving and when hazardous activities are undertaken in poor illumination.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection18"></a><a name="section-14.3"></a><p></p>
<h2>
17.3	Accommodative Spasm</h2>
<p class="First">IsoptoÂ® Carpine ophthalmic solution may cause problems when changing focus between near objects and distant objects. Do not drive or use machinery if vision is not clear.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection19"></a><a name="section-14.4"></a><p></p>
<h2>
17.4	Contact Lens Wear</h2>
<p class="First">Contact lens should be removed prior to the instillation of IsoptoÂ® Carpine ophthalmic solution. Wait 10 minutes after dosing before reinserting contact lenses.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection20"></a><a name="section-14.5"></a><p></p>
<h2>
17.5	Concomitant Topical Ocular Therapy</h2>
<p class="First">If more than one topical ophthalmic medication is being used, the medicines must be administered at least 5 minutes apart.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection21"></a><a name="section-14.6"></a><p></p>
<h2>
17.6	Systemic Exposure</h2>
<p class="First">To limit exposure to pilocarpine to the eye alone, close eyes gently and apply pressure with finger to the corner of eye by the nose for 2 minutes after instillation of IsoptoÂ® Carpine ophthalmic solution.</p>
<p><span class="Bold">Rx Only<br></span>Printed in USA<br>Â©2009, 2010 Alcon, Inc.<br><br><span class="Bold">ALCON LABORATORIES, INC.<br></span>6201 South Freeway<br>Fort Worth, Texas 76134 USA<br>1-800-757-9195<br><br><span class="Bold">9005884-0910</span></p>
<p></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="splSectionPDP"></a><a name="section-15"></a><p></p>
<h1>
PRINCIPAL DISPLAY PANEL</h1>
<p class="First"><span class="Bold">NDC</span> 0998-0203-15<br><br><span class="Bold">Alcon<span class="Sup">Â®</span><br></span><br><span class="Bold">Isopto<span class="Sup">Â®</span> Carpine 1%<br>(pilocarpine hydrochloride ophthalmic solution)<br></span><br><span class="Bold">15 mL Sterile</span></p>
<div class="Figure"><img alt="Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=22e4c7f4-bbd0-4e74-85da-bb56fc377568&amp;name=carton.jpg"></div>
<div class="Figure"><img alt="Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=22e4c7f4-bbd0-4e74-85da-bb56fc377568&amp;name=label.jpg"></div>
<p></p>
<p></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ISOPTO CARPINEÂ 		
					</strong><br><span class="contentTableReg">pilocarpine hydrochloride solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0998-0203</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PILOCARPINE HYDROCHLORIDE</strong> (PILOCARPINE) </td>
<td class="formItem">PILOCARPINE HYDROCHLORIDE</td>
<td class="formItem">10Â mg Â inÂ 1Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BENZALKONIUM CHLORIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE 2910 (15 MPA.S)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BORIC ACID</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CITRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0998-0203-15</td>
<td class="formItem">15 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA200890</td>
<td class="formItem">01/01/1974</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ISOPTO CARPINEÂ 		
					</strong><br><span class="contentTableReg">pilocarpine hydrochloride solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0998-0204</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PILOCARPINE HYDROCHLORIDE</strong> (PILOCARPINE) </td>
<td class="formItem">PILOCARPINE HYDROCHLORIDE</td>
<td class="formItem">20Â mg Â inÂ 1Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BENZALKONIUM CHLORIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE 2910 (15 MPA.S)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BORIC ACID</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CITRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0998-0204-15</td>
<td class="formItem">15 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA200890</td>
<td class="formItem">01/01/1974</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ISOPTO CARPINEÂ 		
					</strong><br><span class="contentTableReg">pilocarpine hydrochloride solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0998-0206</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PILOCARPINE HYDROCHLORIDE</strong> (PILOCARPINE) </td>
<td class="formItem">PILOCARPINE HYDROCHLORIDE</td>
<td class="formItem">40Â mg Â inÂ 1Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BENZALKONIUM CHLORIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE 2910 (15 MPA.S)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BORIC ACID</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CITRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0998-0206-15</td>
<td class="formItem">15 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA200890</td>
<td class="formItem">01/01/1974</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Alcon Laboratories, Inc.
							(008018525)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant -Â </span>Alcon Laboratories, Inc. (008018525)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Alcon Laboratories, Inc.</td>
<td class="formItem"></td>
<td class="formItem">008018525</td>
<td class="formItem">MANUFACTURE(0998-0206)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 6/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>fb16671e-a0d5-88d6-dc8f-fd78e24be302</div>
<div>Set id: 22e4c7f4-bbd0-4e74-85da-bb56fc377568</div>
<div>Version: 7</div>
<div>Effective Time: 20110621</div>
</div>
</div>Â <div class="DistributorName">Alcon Laboratories, Inc.</div></p>
</body></html>
